Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
65 results about "Hematologic cancer" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Caused when our bone marrow makes too many blood cells, cancers of the blood lead to anemia, frequent infections and excessive bleeding. Common types of blood cancer, also called hematologic cancer, are leukemia, lymphoma and multiple myeloma.
1H-pyrazolo[3,4-b]pyridines and therapeutic uses thereof
Provided herein are compounds according to Formula I and pharmaceutically acceptable salts thereof, and compositions comprising the same, for use in various methods, including treating cancers such as colon, ovarian, pancreatic, breast, liver, prostate and hematologic cancers:
![1H-pyrazolo[3,4-<i>b</i>]pyridines and therapeutic uses thereof](https://images-eureka-patsnap-com.libproxy1.nus.edu.sg/patent_img/a208a788-d164-4d46-bdfe-b503be2f9d03/US08450340-20130528-C00001.png "1H-pyrazolo[3,4-<i>b</i>]pyridines and therapeutic uses thereof")
![1H-pyrazolo[3,4-<i>b</i>]pyridines and therapeutic uses thereof](https://images-eureka-patsnap-com.libproxy1.nus.edu.sg/patent_img/a208a788-d164-4d46-bdfe-b503be2f9d03/US08450340-20130528-C00002.png "1H-pyrazolo[3,4-<i>b</i>]pyridines and therapeutic uses thereof")
![1H-pyrazolo[3,4-<i>b</i>]pyridines and therapeutic uses thereof](https://images-eureka-patsnap-com.libproxy1.nus.edu.sg/patent_img/a208a788-d164-4d46-bdfe-b503be2f9d03/US08450340-20130528-C00003.png "1H-pyrazolo[3,4-<i>b</i>]pyridines and therapeutic uses thereof")
Owner:BIOSPLICE THERAPEUTICS INC
1h-pyrazolo[3,4-b]pyridines and therapeutic uses thereof
ActiveUS20110190290A1Antagonize activityBiocideSenses disorderPancreas CancersPharmaceutical medicine
Provided herein are compounds according to Formula I and pharmaceutically acceptable salts thereof, and compositions comprising the same, for use in various methods, including treating cancers such as colon, ovarian, pancreatic, breast, liver, prostate and hematologic cancers:
![1h-pyrazolo[3,4-b]pyridines and therapeutic uses thereof](https://images-eureka-patsnap-com.libproxy1.nus.edu.sg/patent_img/b447f0f5-f312-4b8c-a534-1c9837ef1f72/US20110190290A1-20110804-C00001.png "1h-pyrazolo[3,4-b]pyridines and therapeutic uses thereof")
![1h-pyrazolo[3,4-b]pyridines and therapeutic uses thereof](https://images-eureka-patsnap-com.libproxy1.nus.edu.sg/patent_img/b447f0f5-f312-4b8c-a534-1c9837ef1f72/US20110190290A1-20110804-C00002.png "1h-pyrazolo[3,4-b]pyridines and therapeutic uses thereof")
![1h-pyrazolo[3,4-b]pyridines and therapeutic uses thereof](https://images-eureka-patsnap-com.libproxy1.nus.edu.sg/patent_img/b447f0f5-f312-4b8c-a534-1c9837ef1f72/US20110190290A1-20110804-C00003.png "1h-pyrazolo[3,4-b]pyridines and therapeutic uses thereof")
Owner:BIOSPLICE THERAPEUTICS INC
Synergistic Anti-CD47 Therapy for Hematologic Cancers
ActiveUS20120282174A1Immunoglobulins against cell receptors/antigens/surface-determinantsRadioactive preparation carriersSurface markerCD20
Methods are provided for treatment of hematologic cancers, particularly lymphomas and leukemias, including without limitation myelogenous and lymphocytic leukemias. A combination of antibodies specific for CD47; and specific for a cancer associated cell surface marker are administered to the patient, and provide for a synergistic decrease in cancer cell burden. The combination of antibodies may comprise a plurality of monospecific antibodies, or a bispecific or multispecific antibody. Markers of interest include without limitation, CD20, CD22, CD52, CD33; CD96; CD44; CD123; CD97; CD99; PTHR2; and HAVCR2.
Owner:THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIV
Antibodies and antibody fragments targeting sirp-alpha and their use in treating hematologic cancers
Owner:THE GOVERNINIG COUNCIL OF THE UNIV OF TORANTO +2
Composite Profiles of Cell Antigens and Target Signal Transduction Proteins for Analysis and Clinical Management of Hematologic Cancers
InactiveUS20100261204A1Increased riskDetermining prognosisDisease diagnosisBlood/immune system cellsCellular antigensTarget signal
Owner:BECKMAN COULTER INC
Methods for treating hematologic cancers
ActiveUS20160222121A1Radioactive preparation carriersImmunoglobulins against cell receptors/antigens/surface-determinantsOncologyPharmacology
The present invention relates to methods of treating hematologic cancers using a combination of inhibitors of PD-1 or PD-L1 and TIM-3, LAG-3 or CTLA-4. In one embodiment, an inhibitor of PD-1 or PD-L1 is administered in combination with an inhibitor of TIM-3. In another embodiment, an inhibitor of PD-1 or PD-L1 is administered in combination with an inhibitor of LAG-3. In yet another embodiment, an inhibitor of PD-1 or PD-L1 is administered in combination with an inhibitor of CTLA-4.
Owner:THE MEDICAL COLLEGE OF WISCONSIN INC +1
Synergistic anti-CD47 therapy for hematologic cancers
Methods are provided for treatment of hematologic cancers, particularly lymphomas and leukemias, including without limitation myelogenous and lymphocytic leukemias. A combination of antibodies specific for CD47; and specific for a cancer associated cell surface marker are administered to the patient, and provide for a synergistic decrease in cancer cell burden. The combination of antibodies may comprise a plurality of monospecific antibodies, or a bispecific or multispecific antibody. Markers of interest include without limitation, CD20, CD22, CD52, CD33; CD96; CD44; CD123; CD97; CD99; PTHR2; and HAVCR2.
Owner:THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIV
Composite profiles of cell antigens and target signal transduction proteins for analysis and clinical management of hematologic cancers
InactiveUS20070105165A1Increased relapse riskDetermining prognosisDisease diagnosisBlood/immune system cellsCellular antigensTarget signal
The present invention is directed to methods for establishing a composite marker profile for a sample derived from an individual suspected having a neoplastic condition. A composite marker profile of the invention allows for identification of prognostically and therapeutically relevant subgroups of neoplastic conditions and prediction of the clinical course of an individual. The methods of the invention provide tools useful in choosing a therapy for an individual afflicted with a neoplastic condition, including methods for assigning a risk group, methods of predicting an increased risk of relapse, methods of predicting an increased risk of developing secondary complications, methods of choosing a therapy for an individual, methods of determining the efficacy of a therapy in an individual, and methods of determining the prognosis for an individual. In particular, the method of the present invention discloses a method for establishing a composite marker profile that can serve as a prognostic indicator to predict whether the course of a neoplastic condition in a individual will be aggressive or indolent, thereby aiding the clinician in managing the patient and evaluating the modality of treatment to be used. In particular embodiments disclosed herein, the methods of the invention are directed to establishing a composite marker profile for a leukemia selected from the group consisting of Chronic Lymphocytic Leukemia (CLL), Acute Myelogenous Leukemia (AML), Chronic Myelogenous Leukemia (CML), and Acute Lymphocytic Leukemia (ALL).
Owner:BECKMAN COULTER INC +4
Azaindole inhibitors of aurora kinases
Owner:GLAXO SMITHKLINE LLC
Anti-CD19 full humanized antibody or antibody segment as well as method and application thereof
ActiveCN107880128ATo achieve the purpose of healingPolypeptide with localisation/targeting motifImmunoglobulin superfamilyComplementarity determining regionHeavy chain
The invention discloses an anti-CD19 full humanized antibody or antibody segment as well as a method and an application thereof. The antibody or the antibody segment contains a heavy chain and a lightchain, wherein the heavy chain and the light chain comprise variable regions; the variable regions comprise complementary determining regions; the complementary determining regions CDR1, CDR2 and CDR3 of the heavy chain are separately represented by HCDR1, HCDR2 and HCDR3; the complementary determining regions CDR1, CDR2 and CDR3 of the light chain are separately represented by LCDR1, LCDR2 and LCDR3; the amino acid sequence of the HCDR1 comprises SED ID NO: 3; the amino acid sequence of the HCDR2 comprises SEQ ID NO: 4; the amino acid sequence of the HCDR3 comprises SEQ ID NO: 5; the amino acid sequence of the LCDR1 comprises SEQ ID NO: 6; and the amino acid sequence of the LCDR2 comprises SEQ ID NO: 7. The antibody or the antibody segment can be combined with a humanized CD19 protein with high specificity, and by means of engineered expression integration by means of a chimeric antigen receptor cell technology in a cell T, the obtained chimeric antigen receptor cell T can be used for treating hematological cancers related to expression of CD19.
Owner:CHANGZHOU VELOX PHARMA SCI & TECH CO LTD
Method of inhibiting osteoclast activity
InactiveUS20090004196A1Peptide/protein ingredientsAntibody mimetics/scaffoldsMelanomaSquamous Carcinomas
Methods for inhibiting osteoclastogenesis by administering a soluble RANK polypeptide are disclosed. Such methods can be used to treat a variety of different cancers, including bone cancer, multiple myeloma, melanoma, breast cancer, squamous cell carcinoma, lung cancer, prostate cancer, hematologic cancers, head and neck cancer and renal cancer.
Owner:IMMUNEX CORP
Method of inhibition of leukemic stem cells
InactiveUS20110052574A1Enhanced Fc effector functionFunction increaseOrganic active ingredientsImmunoglobulins against cell receptors/antigens/surface-determinantsAntigen bindingLeukemic Stem Cell
Owner:CSL LTD +1
Kits for treatment of hematologic disorders
InactiveUS7408039B2Reduce GVHDSignificant graft-versus-leukemia （GVL） effectBiocideGenetic material ingredientsGraft versus leukaemiaHematological Diseases
The inventors have discovered that hematologic disorders, e.g., both neoplastic (hematologic cancers) and non-neoplastic conditions, can be treated by the induction of mixed chimerism using myeloreductive, but not myeloablative, conditioning. Methods of the invention reduce GVHD, especially GVHD associated with mismatched allogeneic or xenogeneic donor tissue, yet provide, for example, significant graft-versus-leukemia (GVL) effect and the like.
Owner:THE GENERAL HOSPITAL CORP
Uses of hypoxia-inducible factor inhibitors
ActiveUS20120264697A1Avoid maintenanceAvoid survivalOrganic active ingredientsTetrapeptide ingredientsHypoxia-inducible factorsOncology
The present invention relates to treating a hematologic cancer using a Hypoxia- Inducible Factor (HIF inhibitor). The invention also relates to inducing acute myeloid leukemia remission using the HIF inhibitor. The invention further relates to inhibiting a maintenance or survival function of a cancer stem cell (CSC) using the HIF inhibitor.
Owner:ONCOC4 INC
Methods for treating hematologic cancers
ActiveUS10570204B2Radioactive preparation carriersImmunoglobulins against cell receptors/antigens/surface-determinantsOncologyPharmacology
The present invention relates to methods of treating hematologic cancers using a combination of inhibitors of PD-1 or PD-L1 and TIM-3, LAG-3 or CTLA-4. In one embodiment, an inhibitor of PD-1 or PD-L1 is administered in combination with an inhibitor of TIM-3. In another embodiment, an inhibitor of PD-1 or PD-L1 is administered in combination with an inhibitor of LAG-3. In yet another embodiment, an inhibitor of PD-1 or PD-L1 is administered in combination with an inhibitor of CTLA-4.
Owner:THE MEDICAL COLLEGE OF WISCONSIN INC +1
Treatment of hematologic disorders
InactiveUS7892578B2Reduce GVHDRemarkable effectBiocideOrganic active ingredientsGraft versus leukaemiaHematological Diseases
Owner:THE GENERAL HOSPITAL CORP
Anti-cd7 chimeric antigen receptor and method of use thereof
ActiveUS20190144522A1Polypeptide with localisation/targeting motifImmunoglobulin superfamilyAntigen receptorChimeric antigen receptor
A nucleic acid construct and mammalian cell harboring nucleic acids encoding an anti-CD7 chimeric antigen receptor are provided. Methods for treating cancer, in particular a hematologic cancer, using the nucleic acid construct or mammalian cell are also described.
Owner:ST JUDE CHILDRENS RES HOSPITAL INC
Chemical compounds
This invention relates to certain unsaturated fatty acid derivatives of therapeutically active 1,3-dioxolane nucleoside analogues and to pharmaceutical formulations containing them. The said derivatives are referred to as “Compounds of formula I” herein. Compounds of formula I can be used in the treatment of a cancerous disease. Treatment of both solid tumours and haematological cancers such as leukaemias, lymphomas and multiple myelomas are included.
Owner:CLAVIS PHARMA AS
Method of inhibition of leukemic stem cells
InactiveUS20130230510A1Function increaseOrganic active ingredientsAntibody ingredientsAntigen bindingLeukemic Stem Cell
A method for inhibition of leukemic stem cells expressing IL-3R.alpha.; (CD 123), comprises contacting the cells with an antigen binding molecule comprising a Fc region or a modified Fc region having enhanced Fc effector function, wherein the antigen binding molecule binds selectively to IL-3R.alpha. (CD123). The invention includes the treatment of a hematologic cancer condition in a patient by administration to the patient of an effective amount of the antigen binding molecule.
Owner:UNIV HEALTH NETWORK +1
Methods and compositions for treatment of hematologic cancers
The present invention relates to oncolytic picornaviruses and methods and compositions for treating subjects having hematologic cancers. These include methods and compositions for treatment of myeloma, using disclosed Picornavirus such as Coxsackievirus, in methods of direct or indirect administration to subjects and ex vivo purging of malignant cells within auto grafts prior to transplantation.
Owner:MERCK & CO INC
Treatment of hematologic tumors and cancers with beta-lapachone, a broad spectrum anti-cancer agent
The present invention provides for methods that utilize agents effective in the treatment of hematologic cancers and pre-cancerous hematologic cancer conditions. Moreover, the present invention provides agents capable of acting as an inhibitor of cell proliferation in hematologic cells.
Owner:ARQULE INC
Mannan-binding lectin (MBL) in the treatment of immunocompromised conditions asssociated with cancer
The present invention pertains to the use of subunits and oligomers of mannan- binding lectin (MBL) in prophylactic and / or curative treatment of an immunocompromised individual such as subjects suffering from solid tumors or haematological cancers. Solid tumors include such as female cancers, male cancers, cancers of the respiratory system, cancers of the gastro intestinal system, the renal system and further subjects suffering from thyroid cancer and melanomas. Haematological cancers include leukaemia, lymphoma and myeloma. The immunocompromised condition of the individual may be due to a cancer disease as mentioned herein or the treatment of said cancer disease.
Owner:内蒂穆恩公司
Compositions and methods to improve the homing and grafting of hematopoetic stem cells
PendingUS20150250883A1Enhancing integrin-mediated bindingOrganic active ingredientsBiocideDiseaseAgonist
Media compositions and methods of enhancing binding of cells to an integrin-binding ligand comprising treating integrin-expressing hematopoietic stem cells ex vivo with an agonist of integrin, wherein the integrin is selected from the group consisting of α4β1, α5β1, α4β7, αvβ3 and αLβ2, and contacting the treated cells ex vivo with an integrin-binding ligand; integrin agonist compounds having the general formula I; methods of treating integrin-expressing cells with such agonists to enhance binding; and therapeutic methods comprising administering agonist-treated cells with minimal exposure agonist compounds to a mammal requiring stem cell transplantation in the management of hematologic cancers and genetic diseases.
Owner:7 HILLS PHARMA
Methods of altering peripheral b cell populations and uses thereof
A method of altering peripheral B cell populations in a subject in need thereof is disclosed. The method comprising administering to the subject a therapeutically effective amount of an agent capable of depleting peripheral B cells in the subject, and wherein the subject does not have a hematologic cancer or an autoimmune disease, thereby altering the peripheral B cell populations in the subject.
Owner:RAPPAPORT FAMILY INSTITUTE FOR RESEACH IN THE MEDICAL SCIENCES
Novel Cancer Indications of Mannan-Binding Lectin (Mbl) in the Treatment of Immunocompromised Individuals
InactiveUS20080214435A1Sufficient immune responseAntibacterial agentsAntimycoticsImmune compromisedOncology
The present invention pertains to the use of subunits and oligomers of mannan-binding lectin (MBL) in prophylactic and / or curative treatment of an immunocompromised individual such as subjects suffering from solid tumors or haematological cancers. Solid tumors include such as female cancers, male cancers, cancers of the respiratory system, cancers of the gastro intestinal system, the renal system and further subjects suffering from thyroid cancer and melanomas. Haematological cancers include leukaemia, lymphoma and myeloma. The immunocompromised condition of the individual may be due to a cancer disease as mentioned herein or the treatment of said cancer disease.
Owner:NAT IMMUNE
Composite profiles of cell antigens and target signal transduction proteins for analysis and clinical management of hematologic cancers
The present invention provides methods for establishing a composite marker profile for a sample derived from an individual suspected having a neoplastic condition. A composite marker profile of the invention allows for identification of prognostically and therapeutically relevant subgroups of neoplastic conditions and prediction of the clinical course of an individual. The methods of the invention provide tools useful in choosing a therapy for an individual afflicted with a neoplastic condition, including methods for assigning a risk group, methods of predicting an increased risk of relapse, methods of predicting an increased risk of developing secondary complications, methods of choosing a therapy for an individual, methods of determining the efficacy of a therapy in an individual, and methods of determining the prognosis for an individual. In particular, the method of the present invention discloses a method for establishing a composite marker profile that can serve as a prognostic indicator to predict whether the course of a neoplastic condition in a individual will be aggressive or indolent, thereby aiding the clinician in managing the patient and evaluating the modality of treatment to be used. In particular embodiments disclosed herein, the methods of the invention are directed to establishing a composite marker profile for a leukemia selected from the group consisting of Chronic Lymphocytic Leukemia (CLL), Acute Myelogenous Leukemia (AML), Chronic Myelogenous Leukemia (CML), and Acute Lymphocytic Leukemia (ALL).
Owner:BECKMAN COULTER INC +4
Fixed drug ratios for treatment of hematopoietic cancers and proliferative disorders
Provided herein are methods for treating cancer by administering a pharmaceutical composition comprising a fixed, non-antagonistic molar ratio of cytarabine and an anthracycline. Such methods are particularly useful in the treatment of patients with advanced hematologic cancers or proliferative disorders.
Owner:CELATOR PHARMA INC
Methods and compositions for treatment of hematologic cancers
The present invention relates to oncolytic Picornaviruses and methods and compositions for treating subjects having hematologic cancers. These include methods and compositions for treatment of myeloma, using disclosed Picornavirus such as Coxsackievirus, in methods of direct or indirect administration to subjects and ex vivo purging of malignant cells within auto grafts prior to transplantation.
Owner:MERCK SHARP & DOHME LLC
Method of inhibiting osteoclast activity
InactiveUS20140178376A1Peptide/protein ingredientsAntibody mimetics/scaffoldsMelanomaSquamous Carcinomas
Methods for inhibiting osteoclastogenesis by administering a soluble RANK polypeptide are disclosed. Such methods can be used to treat a variety of different cancers, including bone cancer, multiple myeloma, melanoma, breast cancer, squamous cell carcinoma, lung cancer, prostate cancer, hematologic cancers, head and neck cancer and renal cancer.
Owner:IMMUNEX CORP
Dioxolane derivates for the treatment of cancer
This invention relates to certain unsaturated fatty acid derivatives of therapeutically active 1,3-dioxolane nucleoside analogues and to pharmaceutical formulations containing them. The said derivatives are referred to as “Compounds of formula (I)” herein. Compounds of formula (I) can be used in the treatment of a cancerous disease. Treatment of both solid tumours and haematological cancers such as leukaemias, lymphomas and multiple myelomas are included.
Owner:CLAVIS PHARMA ASA
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com